BioMarin Pharmaceutical Inc. (LON:0HNC)
58.13
+0.54 (0.93%)
At close: May 27, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $745.15M USD in the quarter ending March 31, 2025, with 14.84% growth. This brings the company's revenue in the last twelve months to $2.95B, up 19.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$2.95B
Revenue Growth
+19.36%
P/S Ratio
3.61
Revenue / Employee
$970.47K
Employees
3,040
Market Cap
8.24B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
BioMarin Pharmaceutical News
- 6 days ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire
- 9 days ago - BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
- 12 days ago - BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover - Investor's Business Daily
- 12 days ago - BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - Seeking Alpha
- 12 days ago - BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma - PRNewsWire
- 16 days ago - BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PRNewsWire
- 25 days ago - A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings - Benzinga
- 26 days ago - BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - Seeking Alpha